1
|
Foster MA, Pontillo G, Davagnanam I, Collorone S, Prados F, Kanber B, Yiannakas MC, Ogunbowale L, Burke A, Gandini Wheeler‐Kingshott CAM, Ciccarelli O, Brownlee W, Barkhof F, Toosy AT. Improving criteria for dissemination in space in multiple sclerosis by including additional regions. Ann Clin Transl Neurol 2024; 11:2572-2582. [PMID: 39078773 PMCID: PMC11514922 DOI: 10.1002/acn3.52170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2024] [Accepted: 07/17/2024] [Indexed: 10/29/2024] Open
Abstract
OBJECTIVE We investigated the effects of adding regions to current dissemination in space (DIS) criteria for multiple sclerosis (MS). METHODS Participants underwent brain, optic nerve, and spinal cord MRI. Baseline DIS was assessed by 2017 McDonald criteria and versions including optic nerve, temporal lobe, or corpus callosum as a fifth region (requiring 2/5), a version with all regions (requiring 3/7) and optic nerve variations requiring 3/5 and 4/5 regions. Performance was evaluated against MS diagnosis (2017 McDonald criteria) during follow-up. RESULTS Eighty-four participants were recruited (53F, 32.8 ± 7.1 years). 2017 McDonald DIS criteria were 87% sensitive (95% CI: 76-94), 73% specific (50-89), and 83% accurate (74-91) in identifying MS. Modified criteria with optic nerve improved sensitivity to 98% (91-100), with specificity 33% (13-59) and accuracy 84% (74-91). Criteria including temporal lobe showed sensitivity 94% (84-98), specificity 50% (28-72), and accuracy 82% (72-90); criteria including corpus callosum showed sensitivity 90% (80-96), specificity 68% (45-86), and accuracy 85% (75-91). Criteria adding all three regions (3/7 required) had sensitivity 95% (87-99), specificity 55% (32-76), and accuracy 85% (75-91). When requiring 3/5 regions (optic nerve as the fifth), sensitivity was 82% (70-91), specificity 77% (55-92), and accuracy 81% (71-89); with 4/5 regions, sensitivity was 56% (43-69), specificity 95% (77-100), and accuracy 67% (56-77). INTERPRETATION Optic nerve inclusion increased sensitivity while lowering specificity. Increasing required regions in optic nerve criteria increased specificity and decreased sensitivity. Results suggest considering the optic nerve for DIS. An option of 3/5 or 4/5 regions preserved specificity, and criteria adding all three regions had highest accuracy.
Collapse
Affiliation(s)
- Michael A. Foster
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
| | - Giuseppe Pontillo
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
- Department of Radiology and Nuclear MedicineAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdamthe Netherlands
- Department of Advanced Biomedical Sciences and Electrical Engineering and Information TechnologyUniversity of Naples Federico IINaplesItaly
| | - Indran Davagnanam
- Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
| | - Sara Collorone
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
| | - Ferran Prados
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, Faculty of Engineering ScienceUniversity College LondonLondonUK
- Universitat Oberta de CatalunyaBarcelonaSpain
| | - Baris Kanber
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, Faculty of Engineering ScienceUniversity College LondonLondonUK
| | - Marios C. Yiannakas
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
| | - Lola Ogunbowale
- Strabismus and Neuro‐Ophthalmology ServiceMoorfields Eye Hospital NHS Foundation TrustLondonUK
| | - Ailbhe Burke
- Strabismus and Neuro‐Ophthalmology ServiceMoorfields Eye Hospital NHS Foundation TrustLondonUK
| | - Claudia A. M. Gandini Wheeler‐Kingshott
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
- Department of Brain and Behavioural SciencesUniversity of PaviaPaviaItaly
| | - Olga Ciccarelli
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
- NIHR University College London Hospitals Biomedical Research CentreLondonUK
| | - Wallace Brownlee
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
- NIHR University College London Hospitals Biomedical Research CentreLondonUK
| | - Frederik Barkhof
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
- Department of Radiology and Nuclear MedicineAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdamthe Netherlands
- Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, Faculty of Engineering ScienceUniversity College LondonLondonUK
- NIHR University College London Hospitals Biomedical Research CentreLondonUK
| | - Ahmed T. Toosy
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain SciencesUniversity College LondonLondonUK
| |
Collapse
|
2
|
Sastre-Garriga J, Vidal-Jordana A, Toosy AT, Enzinger C, Granziera C, Frederiksen J, Ciccarelli O, Filippi M, Montalban X, Tintore M, Pareto D, Rovira À. Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives. Neurology 2024; 103:e209677. [PMID: 39018513 PMCID: PMC11271394 DOI: 10.1212/wnl.0000000000209677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Accepted: 05/17/2024] [Indexed: 07/19/2024] Open
Abstract
The optic nerve is frequently involved in multiple sclerosis (MS). However, MRI of the optic nerve is considered optional in the differential diagnosis of optic neuropathy symptoms either at presentation or in established MS. In addition, unlike spinal cord imaging in comparable scenarios, no role is currently recommended for optic nerve MRI in patients presenting with optic neuritis for its confirmation, to plan therapeutic strategy, within the MS diagnostic framework, nor for the detection of subclinical activity in established MS. In this article, evidence related to these 3 aspects will be summarized and gaps in knowledge will be highlighted, including (1) the acquisition challenges and novel sequences that assess pathologic changes within the anterior visual pathways; (2) the clinical implications of quantitative magnetic resonance studies of the optic nerve, focusing on atrophy measures, magnetization transfer, and diffusion tensor imaging; and (3) the relevant clinical studies performed to date. Finally, an algorithm for the application of optic nerve MRI will be proposed to guide future studies aimed at addressing our knowledge gaps.
Collapse
Affiliation(s)
- Jaume Sastre-Garriga
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Angela Vidal-Jordana
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Ahmed T Toosy
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Christian Enzinger
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Cristina Granziera
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Jette Frederiksen
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Olga Ciccarelli
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Massimo Filippi
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Xavier Montalban
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Mar Tintore
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Deborah Pareto
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| | - Àlex Rovira
- From the Department of Neurology (J.S.-G., A.V.-J., X.M., M.T.), Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; NMR Research Unit (A.T.T.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology and Division of Neuroradiology (C.E.), Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Austria; Translational Imaging in Neurology (ThINk) Basel (C.G.), Department of Biomedical Engineering, Faculty of Medicine, University of Basel; Neurology Department and MS Center, University Hospital Basel, Switzerland; Department of Neurology (J.F.), Rigshospitalet-Glostrup, and University of Copenhagen, Glostrup, Denmark; NMR Research Unit (O.C.), Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research, United Kingdom; Neuroimaging Research Unit (M.F.), Division of Neuroscience and Neurology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy; and Section of Neuroradiology and Magnetic Resonance Unit (D.P., A.R.), Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain
| |
Collapse
|
3
|
Rovira À, Vidal-Jordana A, Auger C, Sastre-Garriga J. Optic Nerve Imaging in Multiple Sclerosis and Related Disorders. Neuroimaging Clin N Am 2024; 34:399-420. [PMID: 38942524 DOI: 10.1016/j.nic.2024.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/30/2024]
Abstract
Optic neuritis is a common feature in multiple sclerosis and in 2 other autoimmune demyelinating disorders such as aquaporin-4 IgG antibody-associated neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Although serologic testing is critical for differentiating these different autoimmune-mediated disorders, MR imaging, which is the preferred imaging modality for assessing the optic nerve, can provide valuable information, suggesting a specific diagnosis and guiding the appropriate serologic testing.
Collapse
Affiliation(s)
- Àlex Rovira
- Department of Radiology, Section of Neuroradiology, Vall d'Hebron University Hospital, Autonomous Univesity of Barcelona, Barcelona, Spain.
| | - Angela Vidal-Jordana
- Department of Neurology, Centro de Esclerosis Múltiple de Catalunya (Cemcat), Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain
| | - Cristina Auger
- Department of Radiology, Section of Neuroradiology, Vall d'Hebron University Hospital, Autonomous Univesity of Barcelona, Barcelona, Spain
| | - Jaume Sastre-Garriga
- Department of Neurology, Centro de Esclerosis Múltiple de Catalunya (Cemcat), Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain
| |
Collapse
|
4
|
Comparison of 3D Double Inversion Recovery (DIR) Versus 3D Fluid Attenuated Inversion Recovery (FLAIR) in Precise Diagnosis of Acute Optic Neuritis. Eur J Radiol 2022; 155:110505. [DOI: 10.1016/j.ejrad.2022.110505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2022] [Revised: 08/22/2022] [Accepted: 08/28/2022] [Indexed: 11/23/2022]
|
5
|
Costagli M, Lapucci C, Zacà D, Bruschi N, Schiavi S, Castellan L, Stemmer A, Roccatagliata L, Inglese M. Improved detection of multiple sclerosis lesions with T2-prepared double inversion recovery at 3T. J Neuroimaging 2022; 32:902-909. [PMID: 35776654 PMCID: PMC9544719 DOI: 10.1111/jon.13021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/14/2022] [Accepted: 06/15/2022] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND AND PURPOSE Double inversion recovery (DIR) imaging is used in multiple sclerosis (MS) clinical protocols to improve the detection of cortical and juxtacortical gray matter lesions by nulling confounding signals originating from the cerebrospinal fluid and white matter. Achieving a high isotropic spatial resolution, to depict the neocortex and its typically small lesions, is challenged by the reduced signal-to-noise ratio (SNR) determined by multiple tissue signal nulling. Here, we evaluate both conventional and optimized DIR implementations to improve tissue contrast (TC), SNR, and MS lesion conspicuity. METHODS DIR images were obtained from MS patients and healthy controls using both conventional and prototype implementations featuring a T2-preparation module (T2P), to improve SNR and TC, as well as an image reconstruction routine with iterative denoising (ID). We obtained quantitative measures of SNR and TC, and evaluated the visibility of MS cortical, cervical cord, and optic nerve lesions in the different DIR images. RESULTS DIR implementations adopting T2P and ID enabled improving the SNR and TC of conventional DIR. In MS patients, 34% of cortical, optic nerve, and cervical cord lesions were visible only in DIR images acquired with T2P, and not in conventional DIR images. In the studied cases, image reconstruction with ID did not improve lesion conspicuity. CONCLUSIONS DIR with T2P should be preferred to conventional DIR imaging in protocols studying MS patients, as it improves SNR and TC and determines an improvement in cortical, optic nerve, and cervical cord lesion conspicuity.
Collapse
Affiliation(s)
- Mauro Costagli
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Sciences (DINOGMI), University of Genoa, Genova, Italy.,Laboratory of Medical Physicsand Magnetic Resonance, IRCCS Stella Maris, Pisa, Italy
| | - Caterina Lapucci
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Sciences (DINOGMI), University of Genoa, Genova, Italy.,IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | | | - Nicolò Bruschi
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Sciences (DINOGMI), University of Genoa, Genova, Italy
| | - Simona Schiavi
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Sciences (DINOGMI), University of Genoa, Genova, Italy
| | | | | | - Luca Roccatagliata
- IRCCS Ospedale Policlinico San Martino, Genova, Italy.,Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - Matilde Inglese
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Sciences (DINOGMI), University of Genoa, Genova, Italy.,IRCCS Ospedale Policlinico San Martino, Genova, Italy
| |
Collapse
|
6
|
Denis M, Woillez JP, Smirnov VM, Drumez E, Lannoy J, Boucher J, Zedet M, Pruvo JP, Labreuche J, Zephir H, Leclerc X, Outteryck O. Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss. NEUROLOGY - NEUROIMMUNOLOGY NEUROINFLAMMATION 2022; 9:9/2/e1135. [PMID: 35091465 PMCID: PMC8802684 DOI: 10.1212/nxi.0000000000001135] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Accepted: 12/03/2021] [Indexed: 11/15/2022]
Abstract
Background and Objectives Acute optic neuritis (ON) is a classical presenting symptom of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and anti–MOG-associated disorders. The resulting visual impairment is variable and can be severe. Clinicians are in need of predictive biomarkers to optimize the management of acute ON. In this longitudinal study (IRMANO, NCT03651662), we evaluated the ability of optic nerve lesion length measured on MRI at the acute phase of ON to predict retinal neuro-axonal loss and visual impairment at a chronic stage. Methods We conducted a longitudinal study (IRMANO, NCT03651662) of patients who presented a clinical episode of ON (≤8 weeks). All patients underwent a retinal optical coherence tomography (OCT) and a brain/optic nerve MRI, including 3D double-inversion recovery (DIR) sequence at the acute phase of ON and 12 months later. Primary outcomes were optic nerve DIR hypersignal lesion length, macular ganglion cell–inner plexiform layer (GCIPL) volume measured on OCT, and low-contrast monocular visual acuity (LCMVA). Results The study group included 51 patients (33 women, mean age of 32.4 years ± 7.9). We recruited patients with a clinically isolated syndrome (n = 20), a relapsing-remitting MS (n = 23), an isolated ON (n = 6), and a first clinical episode of NMOSD (n = 2). Optic nerve DIR hypersignal was observed in all but 1 symptomatic optic nerves. At inclusion, the mean optic nerve lesion length (in mm) was 12.35 ± 5.98. The mean GCIPL volume (in mm3) significantly decreased between inclusion (1.90 ± 0.18) and M12 (1.67 ± 0.21; p < 0.0001). Optic nerve lesion length at inclusion was significantly associated with GCIPL thinning (estimate ± SD; −0.012 ± 0.004; p = 0.0016) and LCMVA at M12 (0.016 ± 0.003; p < 0.001). Optic nerve lesion length significantly increased at M12 (15.76 ± 8.70; p = 0.0007). The increase in optic nerve lesion length was significantly associated with the GCIPL thinning between inclusion and M12 (−0.012 ± 0.003; p = 0.0011). Discussion At the acute phase of ON, optic nerve lesion length is an imaging biomarker predictive of retinal neuro-axonal loss and chronic visual impairment, which can help to stratify future therapeutic strategies in acute ON. Classification of Evidence This study provides Class I evidence that optic nerve lesion length measured on MRI during the acute phase of a first episode of ON is associated with long-term retinal neuro-axonal loss and visual impairment.
Collapse
|
7
|
Rovira À, Auger C. Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis. Expert Rev Neurother 2021; 21:895-911. [PMID: 34275399 DOI: 10.1080/14737175.2021.1957832] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Magnetic resonance imaging (MRI) is an essential paraclinical test to establish an accurate and early diagnosis of multiple sclerosis (MS), which is based on the application of the McDonald criteria. AREAS COVERED The objective of this article is to analyze, based on publicly available database since the publication of the 2017 McDonald diagnostic criteria, the clinical impact of these criteria, to discuss the potential inclusion within these criteria of the optic nerve to demonstrate dissemination in space, and to guide the acquisition and interpretation of MRI scans for diagnostic purposes. Finally, the authors will review emerging MRI features that could improve the specificity of MRI in the diagnosis of MS and consequently minimize the misdiagnosis of this disease. EXPERT OPINION Although the optic nerve has not been included as one of the topographies required to demonstrate demyelinating lesion disseminated in space in the 2017 McDonald criteria, new studies seem to show some improvement in the sensitivity of these criteria when this topography is considered. New radiological findings such as the central vein sign and iron rims, should be considered within the typical MRI features of this disease with the objective of minimizing MRI-based diagnostic errors.
Collapse
Affiliation(s)
- Àlex Rovira
- Section of Neuroradiology (Department of Radiology), Hospital Universitari Vall d'Hebron, Universitat Autònoma De Barcelona, Barcelona, Spain.,Vall d´Hebron Research Institute, Barcelona, Spain
| | - Cristina Auger
- Section of Neuroradiology (Department of Radiology), Hospital Universitari Vall d'Hebron, Universitat Autònoma De Barcelona, Barcelona, Spain.,Vall d´Hebron Research Institute, Barcelona, Spain
| |
Collapse
|
8
|
Vidal-Jordana A, Rovira A, Arrambide G, Otero-Romero S, Río J, Comabella M, Nos C, Castilló J, Galan I, Cabello S, Moncho D, Rahnama K, Thonon V, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Auger C, Sastre-Garriga J, Montalban X, Tintoré M. Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. Neurology 2020; 96:e482-e490. [PMID: 33328323 PMCID: PMC7905792 DOI: 10.1212/wnl.0000000000011339] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Accepted: 09/01/2020] [Indexed: 11/27/2022] Open
Abstract
Objective To assess the added value of the optic nerve region (by using visual evoked potentials [VEPs]) to the current diagnostic criteria. Methods From the Barcelona clinically isolated syndrome (CIS) cohort, patients with complete information to assess dissemination in space (DIS), the optic nerve region, and dissemination in time at baseline (n = 388) were selected. Modified DIS (modDIS) criteria were constructed by adding the optic nerve to the current DIS regions. The DIS and modDIS criteria were evaluated with univariable Cox proportional hazard regression analyses with the time to the second attack as the outcome. A subset of these patients who had at least 10 years of follow-up or a second attack occurring within 10 years (n = 151) were selected to assess the diagnostic performance. The analyses were also performed according to CIS topography (optic neuritis vs non–optic neuritis). Results The addition of the optic nerve as a fifth region improved the diagnostic performance by slightly increasing the accuracy (2017 DIS 75.5%, modDIS 78.1%) and the sensitivity (2017 DIS 79.2%, modDIS 82.3%) without lowering the specificity (2017 DIS 52.4%, modDIS 52.4%). When the analysis was conducted according to CIS topography, the modDIS criteria performed similarly in both optic neuritis and non–optic neuritis CIS. Conclusion The addition of the optic nerve, assessed by VEP, as a fifth region in the current DIS criteria slightly improves the diagnostic performance because it increases sensitivity without losing specificity.
Collapse
Affiliation(s)
- Angela Vidal-Jordana
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada.
| | - Alex Rovira
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Georgina Arrambide
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Susana Otero-Romero
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Jordi Río
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Manuel Comabella
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Carlos Nos
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Joaquin Castilló
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Ingrid Galan
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Sergio Cabello
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Dulce Moncho
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Kimia Rahnama
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Vanessa Thonon
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Breogan Rodríguez-Acevedo
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Ana Zabalza
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Luciana Midaglia
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Cristina Auger
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Jaume Sastre-Garriga
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Xavier Montalban
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| | - Mar Tintoré
- From the Servicio de Neurología-Neuroinmunología (A V.-J., G.A., S.O.-R., J.R., M.C., C.N., J.C., I.G., S.C., B.R.-A., A.Z., L.M., J.S.-G., X.M., M.T.), Centro de Esclerosis Múltiple de Catalunya (Cemcat), Sección de Neuroradiologia (A.R., C.A.), Servei de Radiologia, Servicio de Medicina Preventiva y Epidemiologia (S.O.-R.), and Servicio de Neurofisiología Clínica (D.M., K.R., V.T.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital. University of Toronto, Ontario, Canada
| |
Collapse
|
9
|
Villoslada P, Sanchez-Dalmau B, Galetta S. Optical coherence tomography: A useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis. Neurology 2020; 95:239-240. [PMID: 32723803 DOI: 10.1212/wnl.0000000000009840] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Pablo Villoslada
- From Stanford University (P.V.), CA; Hospital Clinic (P.V., B.S.-D.), University of Barcelona, Spain; and NYU Langone Health (S.G.), New York.
| | - Bernardo Sanchez-Dalmau
- From Stanford University (P.V.), CA; Hospital Clinic (P.V., B.S.-D.), University of Barcelona, Spain; and NYU Langone Health (S.G.), New York
| | - Steven Galetta
- From Stanford University (P.V.), CA; Hospital Clinic (P.V., B.S.-D.), University of Barcelona, Spain; and NYU Langone Health (S.G.), New York
| |
Collapse
|
10
|
Outteryck O, Lopes R, Drumez É, Labreuche J, Lannoy J, Hadhoum N, Boucher J, Vermersch P, Zedet M, Pruvo JP, Zéphir H, Leclerc X. Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome. Neurology 2020; 95:e733-e744. [DOI: 10.1212/wnl.0000000000009832] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2019] [Accepted: 02/06/2020] [Indexed: 12/24/2022] Open
Abstract
ObjectiveTo evaluate the ability of intereye retinal thickness difference (IETD) measured by optical coherence tomography (OCT) to detect asymptomatic optic nerve involvement in clinically isolated syndrome (CIS).MethodsWe conducted a cross-sectional study of patients who recently presented a CIS (≤4.5 months). All patients underwent OCT and brain/optic nerve MRI. Optic nerve involvement was defined clinically (episode of optic neuritis [ON] or not) and radiologically (optic nerve hypersignal on 3D double inversion recovery [3D-DIR]). We evaluated the sensitivity and specificity of previously published IETD thresholds and report the observed optimal thresholds for identifying symptomatic optic nerve involvement but also for identifying asymptomatic optic nerve involvement (optic nerve hypersignal without ON history). Primary outcomes were ganglion cell–inner plexiform layer (GC-IPL) and peripapillary retinal nerve fiber layer IETD.ResultsThe study group consisted of 130 patients. In the CIS with ON group, 3D-DIR showed a hypersignal in all 41 symptomatic optic nerves and in 11 asymptomatic optic nerves. In the CIS without ON group, 3D-DIR showed a unilateral optic nerve hypersignal in 22 patients and a bilateral optic nerve hypersignal in 7 patients. For the detection of symptomatic and asymptomatic optic nerve lesion, GC-IPL IETD had better performance. We found an optimal GC-IPL IETD threshold ≥2.83 µm (sensitivity 88.2, specificity 83.3%) for the detection of symptomatic lesions and an optimal GC-IPL IETD ≥1.42 µm (sensitivity 89.3%, specificity 72.6%) for the detection of asymptomatic lesions.ConclusionsDetection of asymptomatic optic nerve lesions in CIS requires lower IETD thresholds than previously reported. GC-IPL IETD represents an alternative biomarker to MRI for the detection of asymptomatic optic nerve lesions.Classification of evidenceThis study provides Class I evidence that OCT accurately identifies asymptomatic optic nerve involvement in patients with CIS.
Collapse
|
11
|
Davion JB, Lopes R, Drumez É, Labreuche J, Hadhoum N, Lannoy J, Vermersch P, Pruvo JP, Leclerc X, Zéphir H, Outteryck O. Asymptomatic optic nerve lesions: An underestimated cause of silent retinal atrophy in MS. Neurology 2020; 94:e2468-e2478. [PMID: 32434868 DOI: 10.1212/wnl.0000000000009504] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Accepted: 01/14/2020] [Indexed: 12/31/2022] Open
Abstract
OBJECTIVE To evaluate the frequency of asymptomatic optic nerve lesions and their role in the asymptomatic retinal neuroaxonal loss observed in multiple sclerosis (MS). METHODS We included patients with remitting-relapsing MS in the VWIMS study (Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis) (ClinicalTrials.gov Identifier: 03656055). Included patients underwent optical coherence tomography (OCT), optic nerve and brain MRI, and low-contrast visual acuity measurement. In eyes of patients with MS without optic neuritis (MS-NON), an optic nerve lesion on MRI (3D double inversion recovery [DIR] sequence) was considered as an asymptomatic lesion. We considered the following OCT/MRI measures: peripapillary retinal nerve fiber layer thickness, macular ganglion cell + inner plexiform layer (mGCIPL) volumes, optic nerve lesion length, T2 lesion burden, and fractional anisotropy within optic radiations. RESULTS An optic nerve lesion was detected in half of MS-NON eyes. Compared to optic nerves without any lesion and independently of the optic radiation lesions, the asymptomatic lesions were associated with thinner inner retinal layers (p < 0.0001) and a lower contrast visual acuity (p ≤ 0.003). Within eyes with asymptomatic optic nerve lesions, optic nerve lesion length was the only MRI measure significantly associated with retinal neuroaxonal loss (p < 0.03). Intereye mGCIPL thickness difference (IETD) was lower in patients with bilateral optic nerve DIR hypersignal compared to patients with unilateral hypersignal (p = 0.0317). For the diagnosis of history of optic neuritis, sensitivity of 3D DIR and of mGCIPL IETD were 84.9% and 63.5%, respectively. CONCLUSIONS Asymptomatic optic nerve lesions are an underestimated and preponderant cause of retinal neuroaxonal loss in MS. 3D DIR sequence may be more sensitive than IETD measured by OCT for the detection of optic nerve lesions.
Collapse
Affiliation(s)
- Jean-Baptiste Davion
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Renaud Lopes
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Élodie Drumez
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Julien Labreuche
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Nawal Hadhoum
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Julien Lannoy
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Patrick Vermersch
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Jean-Pierre Pruvo
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Xavier Leclerc
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Hélène Zéphir
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France
| | - Olivier Outteryck
- From the Department of Neuroradiology, INSERM, U1171-Degenerative and Vascular Cognitive Disorders (J.-B.D., R.L., J.-P.P., X.L., O.O.), Department of Biostatistics, EA 2694-Santé Publique: Épidémiologie et Qualité des Soins (É.D., J.L.), and Department of Neurology, INSERM, U995-Lille Inflammation Research International Center (N.H., J.L., P.V., H.Z.), CHU Lille, Université de Lille, France.
| |
Collapse
|
12
|
Grzegorski T, Losy J. What do we currently know about the clinically isolated syndrome suggestive of multiple sclerosis? An update. Rev Neurosci 2020; 31:335-349. [DOI: 10.1515/revneuro-2019-0084] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Accepted: 09/22/2019] [Indexed: 12/31/2022]
Abstract
AbstractMultiple sclerosis (MS) is a chronic, demyelinating, not fully understood disease of the central nervous system. The first demyelinating clinical episode is called clinically isolated syndrome (CIS) suggestive of MS. Although the most common manifestations of CIS are long tracts dysfunction and unilateral optic neuritis, it can also include isolated brainstem syndromes, cerebellar involvement, and polysymptomatic clinical image. Recently, the frequency of CIS diagnosis has decreased due to the more sensitive and less specific 2017 McDonald criteria compared with the revisions from 2010. Not all patients with CIS develop MS. The risk of conversion can be estimated based on many predictive factors including epidemiological, ethnical, clinical, biochemical, radiological, immunogenetic, and other markers. The management of CIS is nowadays widely discussed among clinicians and neuroscientists. To date, interferons, glatiramer acetate, teriflunomide, cladribine, and some other agents have been evaluated in randomized, placebo-controlled, double-blind studies relying on large groups of patients with the first demyelinating event. All of these drugs were shown to have beneficial effects in patients with CIS and might be used routinely in the future. The goal of this article is to explore the most relevant topics regarding CIS as well as to provide the most recent information in the field. The review presents CIS definition, classification, clinical image, predictive factors, and management. What is more, this is one of very few reviews summarizing the topic in the light of the 2017 McDonald criteria.
Collapse
Affiliation(s)
- Tomasz Grzegorski
- Department of Clinical Neuroimmunology, Chair of Neurology, Poznan University of Medical Sciences, 49 Przybyszewskiego Street, 60-355Poznan, Poland
| | - Jacek Losy
- Department of Clinical Neuroimmunology, Chair of Neurology, Poznan University of Medical Sciences, 49 Przybyszewskiego Street, 60-355Poznan, Poland
| |
Collapse
|
13
|
London F, Zéphir H, Drumez E, Labreuche J, Hadhoum N, Lannoy J, Hodel J, Vermersch P, Pruvo JP, Leclerc X, Outteryck O. Optical coherence tomography: a window to the optic nerve in clinically isolated syndrome. Brain 2019; 142:903-915. [PMID: 30847470 DOI: 10.1093/brain/awz038] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Revised: 12/19/2018] [Accepted: 12/31/2018] [Indexed: 12/25/2022] Open
Abstract
In this study, we aimed to evaluate the association of asymptomatic optic nerve demyelinating lesion in patients presenting a clinically isolated syndrome with the asymptomatic retinal neuro-axonal loss previously reported at clinically isolated syndrome. We prospectively recruited 66 patients presenting a clinically isolated syndrome and 66 healthy control subjects matched according to age and gender. All patients underwent brain magnetic resonance imaging including 3D-double inversion recovery (DIR) sequence, optical coherence tomography examination and visual function evaluation, at 2.5-4.5 months after CIS. Evaluation criteria were presence and length of optic nerve DIR hypersignal, retinal layers (including ganglion cell inner plexiform layer and inner nuclear layer) thickness/volume, and low contrast monocular vision acuity (number of letters correctly identified). All clinically isolated syndrome eyes with past history of optic neuritis (CIS-ON) presented an optic nerve DIR hypersignal. We observed asymptomatic optic nerve DIR hypersignal in 22.2% of clinically isolated syndrome eyes without optic neuritis (CIS-NON). In comparison with healthy control, GCIPL volume (in mm3) was significantly lower in CIS-ON eyes [β (95% confidence interval, CI) = -0.121 (-0.168 to -0.074); P < 0.0001], and to a lesser extent in CIS-NON [β (95% CI) = -0.023 (-0.039 to -0.008); P = 0.004]. In comparison to healthy controls, eyes with asymptomatic optic nerve DIR hypersignal presented significantly lower macular ganglion cell inner plexiform layer volume [β (95% CI) = -0.043 (-0.068 to -0.019); P = 0.001], and eyes without did not [β (95% CI) = -0.016 (-0.034 to 0.003); P = 0.083]. Among CIS-NON, macular ganglion cell inner plexiform layer volume decrease was associated with asymptomatic optic nerve DIR hypersignal independently of optic radiations T2 lesions and primary visual cortex volumes (P = 0.012). Symptomatic optic nerve DIR hypersignal were significantly longer (13.8 ± 6.7 mm) than asymptomatic optic nerve hypersignal (10.0 ± 5.5 mm; P = 0.047). Length of optic nerve DIR hypersignal was significantly associated with thinner inner retinal layers (P ≤ 0.001), thicker inner nuclear layer (P = 0.017) and lower low contrast monocular vision acuity (P < 0.05). Compared to healthy control, low contrast monocular vision acuity was significantly lower in CIS-ON eyes (P < 0.0001) and CIS-NON eyes with (P = 0.03) or without asymptomatic optic nerve DIR hypersignal (P = 0.0005). Asymptomatic demyelinating optic nerve DIR hypersignal at the earliest clinical stage of multiple sclerosis is frequent and associated with asymptomatic retinal neuro-axonal loss reported at clinically isolated syndrome stage. Length of optic nerve DIR hypersignal is a biomarker of retinal neuro-axonal loss and visual disability at clinically isolated syndrome stage. Visual disability of clinically isolated syndrome eyes without clinical and subclinical optic nerve involvement might be due to missed optic nerve lesions on MRI. At the earliest clinical stage of multiple sclerosis, our results support considering optical coherence tomography as a window to the optic nerve rather than to the brain.
Collapse
Affiliation(s)
- Frédéric London
- University of Lille (UMR995), Department of Neurology, Roger Salengro Hospital, Lille, France
| | - Hélène Zéphir
- University of Lille (UMR995), Department of Neurology, Roger Salengro Hospital, Lille, France
| | - Elodie Drumez
- University of Lille, CHU Lille, EA 2694 - Santé publique : épidémiologie et qualité des soins, F-59000 Lille, France
| | - Julien Labreuche
- University of Lille, CHU Lille, EA 2694 - Santé publique : épidémiologie et qualité des soins, F-59000 Lille, France
| | - Nawal Hadhoum
- University of Lille (UMR995), Department of Neurology, Roger Salengro Hospital, Lille, France
| | - Julien Lannoy
- University of Lille (UMR995), Department of Neurology, Roger Salengro Hospital, Lille, France
| | - Jérôme Hodel
- University of Lille (UMR1171), Department of Neuroradiology, Roger Salengro Hospital, Lille, France.,University of Paris Est Créteil, Department of Neuroradiology, Hopital Henri Mondor, Créteil, Paris, France
| | - Patrick Vermersch
- University of Lille (UMR995), Department of Neurology, Roger Salengro Hospital, Lille, France
| | - Jean-Pierre Pruvo
- University of Lille (UMR1171), Department of Neuroradiology, Roger Salengro Hospital, Lille, France
| | - Xavier Leclerc
- University of Lille (UMR1171), Department of Neuroradiology, Roger Salengro Hospital, Lille, France
| | - Olivier Outteryck
- University of Lille (UMR1171), Department of Neuroradiology, Roger Salengro Hospital, Lille, France
| |
Collapse
|